Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
Aptose Biosciences, Inc.
November 4, 2021, 9:00 AM·3 min read
In this article:
HM43239 Data Accepted for Oral Presentation; Data for Luxeptinib and APTO-253 Accepted for Poster Presentation
SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that clinical data for HM43239, a myeloid kinome inhibitor in-licensed by Aptose (announced separately today –
link) is being presented in an oral presentation at the 63rd American Society of Hematology (ASH)
Annual Meeting and Exposition, being held Saturday, December 11 – Monday, December 14, 2021 in Atlanta, GA and virtually. In addition, clinical data for luxeptinib, a dual lymphoid and myeloid inhibitor, and for APTO-253, a small molecule MYC oncogene repressor, have been accepted for poster presentation.